Do you have room in your portfolio for some new ASX 200 blue chip shares?
If you do, it could be worth checking out the three in this article that brokers are feeling bullish on right now.
Here's what you need to know about them:
Cochlear Ltd (ASX: COH)
The first ASX 200 blue chip share that could be a buy is Cochlear. It is a leading hearing solutions company with a global presence.
Thanks to the ageing population tailwind and its ongoing investment in research and development, Cochlear appears well-placed to continue its growth over the next decade.
The team at Citi is very positive on the company and sees potential for strong returns over the next 12 months.
It currently has a buy rating and $300.00 price target on its shares. This implies potential upside of 11% for investors.
Macquarie Group Ltd (ASX: MQG)
Another ASX 200 blue chip share that could be a buy for investors right now is Macquarie.
It is an investment bank with operations across infrastructure, green energy, asset management, and more. Macquarie has a long history of capital discipline and clever deal-making, which has helped to underpin strong returns over the long term.
Morgans believes this can continue. It recently noted that "MQG is a quality franchise, and with a recent pull back in the share price occurring linked to macro and global trade factors, we see upside and move to an ADD (from Hold) recommendation."
As mentioned above, Morgans has put an add rating on its shares with a price target of $223.89. Based on its current share price, this implies potential upside of 8% over the next 12 months. It also expects a 3.5% dividend yield in FY 2026, boosting the total potential return beyond 11%.
CSL Ltd (ASX: CSL)
Finally, CSL could be an ASX 200 blue chip share to buy. It is a world-class biotechnology company best known for its blood plasma therapies.
It could be a top pick due to its combination of defensive characteristics and growth potential. It operates in a very specialised sector with high barriers to entry, and it continually reinvests in R&D to drive long-term product development.
While recent years have seen some growing pains due to global disruptions, CSL's long-term trajectory remains very positive. In fact, Goldman Sachs is forecasting double-digit earnings growth in the coming years.
As a result, it has put a buy rating and $304.60 price target on its shares. This implies potential upside of 23% for investors over the next 12 months.
